B1344

Phase 1Small molecule

TTasly Biopharmaceuticals Co., Ltd.

B1344 is one of 13 small molecule programs targeting Alcoholic Fatty Liver Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcoholic Fatty Liver DiseaseRecruiting

Alcoholic Fatty Liver DiseasePhase 1

Recruiting

Competition

Competitive Landscape

14 competitors in Alcoholic Fatty Liver Disease

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

1 2

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 3

Micardis

Boehringer Ingelheim

Approved

1 4

Prolia

Fosamax

Tricor

2 7

Efruxifermin

Akero Therapeutics

Phase 3

1 8

Trulicity

Eli Lilly

Preclinical

1 9

Niacor

AbbVie

Preclinical

1 10

Invokana

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Trial1 trial

A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects

Unknown status·TTasly Biopharmaceuticals Co., Ltd.·Phase 1·NCT05655221·56 enrolled

Alcoholic Fatty Liver Disease1 trial

a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）

Recruiting·TTasly Biopharmaceuticals Co., Ltd.·Phase 1·NCT07128797·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for B1344. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — B1344 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for B1344. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tasly Biopharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TTasly Biopharmaceuticals Co., Ltd.

B1344

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Trial1 trial

Alcoholic Fatty Liver Disease1 trial

References

Drug Info

Quick Facts

Related News